In patients with cHL, global effector CD8+ T cell responses were greater for LMP2A compared with LMP1 (P = 0·016) and EBNA1 (P < 0·0001) (Supporting information, Fig. S2b). This evidence concerns the gene CD8A and classic Hodgkin lymphoma.